Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels

International Journal of Cardiology

Volumn 168, Issue 4, 2013, Pages 3846-3852

  Tikkanen, Matti J ^a   Fayyad, Rana ^b   Faergeman, Ole ^c   Olsson, Anders G ^d   Wun, Chuan Chuan ^b   Laskey, Rachel ^b   Kastelein, John J ^e   Holme, Ingar ^f   Pedersen, Terje R ^g  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b PFIZER INC   (United States)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^g UNIVERSITY OF OSLO   (Norway)

Author keywords

Alanine aminotransferase; Cardiovascular risk; Coronary heart disease; Fatty liver disease; Liver enzymes; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DICOUMAROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN; WARFARIN; BIOLOGICAL MARKER; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HYPERTRANSAMINASEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; POST HOC ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; TREATMENT OUTCOME; BLOOD; CORONARY DISEASE; MIDDLE AGED; SINGLE BLIND PROCEDURE;

AGED; ALANINE TRANSAMINASE; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; CORONARY DISEASE; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84886254094     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.06.024     Document Type: Article

References (27)

1. Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
2. S.M. Grundy, J.I. Cleeman, and C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines J Am Coll Cardiol 44 2004 720 732
3. Z. Reiner, A.L. Catapano, and G. De Backer ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J 32 2011 1769 1818
4. T. Bader Liver tests are irrelevant when prescribing statins Lancet 376 2010 1882 1883
5. D.E. Cohen, F.A. Anania, and N. Chalasani An assessment of statin safety by hepatologists Am J Cardiol 97 2006 77C 81C
6. A. Kotronen, J. Westerbacka, R. Bergholm, K.H. Pietilainen, and H. Yki-Jarvinen Liver fat in the metabolic syndrome J Clin Endocrinol Metab 92 2007 3490 3497
7. A. Kotronen, and H. Yki-Jarvinen Fatty liver: a novel component of the metabolic syndrome Arterioscler Thromb Vasc Biol 28 2008 27 38
8. J. Westerbacka, A. Corner, and M. Tiikkainen Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk Diabetologia 47 2004 1360 1369
9. T. Miyake, T. Kumagi, and M. Hirooka Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: a community-based cross-sectional study J Gastroenterol 47 2012 696 703
10. L.E. Simental-Mendia, H. Rodriguez-Hernandez, M. Rodriguez-Moran, and F. Guerrero-Romero The alanine aminotransferase to triglycerides ratio as a marker to identify nonalcoholic fatty liver disease Eur J Gastroenterol Hepatol 24 2012 1173 1177
11. B.A. Neuschwander-Tetri, and S.H. Caldwell Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference Hepatology 37 2003 1202 1219
12. E. Vanni, E. Bugianesi, A. Kotronen, S. De Minicis, H. Yki-Jarvinen, and G. Svegliati-Baroni From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 42 2010 320 330
13. R.K. Schindhelm, J.M. Dekker, and G. Nijpels Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study Atherosclerosis 191 2007 391 396
14. C. Meisinger, A. Doring, A. Schneider, and H. Lowel Serum gamma-glutamyltransferase is a predictor of incident coronary events in apparently healthy men from the general population Atherosclerosis 189 2006 297 302
15. V.G. Athyros, A.A. Papageorgiou, and B.R. Mercouris Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study Curr Med Res Opin 18 2002 220 228
16. V.G. Athyros, K. Tziomalos, and T.D. Gossios Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: a post-hoc analysis Lancet 376 2010 1916 1922
17. T.R. Pedersen, O. Faergeman, and J.J. Kastelein Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study Am J Cardiol 94 2004 720 724
18. T.R. Pedersen, O. Faergeman, and J.J. Kastelein High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial JAMA 294 2005 2437 2445
19. L. Hansson, T. Hedner, and B. Dahlöf Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials Blood Press 1 1992 113 119
20. P. Deedwania, P. Barter, and R. Carmena Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study Lancet 368 2006 919 928
21. D.D. Waters, J.R. Guyton, D.M. Herrington, M.P. McGowan, N.K. Wenger, and C. Shear Treating to New Targets study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental benefit? Am J Cardiol 93 2004 154 158
22. C.M. Ballantyne, A.G. Olsson, T.J. Cook, M.F. Mercuri, T.R. Pedersen, and J. Kjekshus Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S Circulation 104 2001 3046 3051
23. T.A. Miettinen, R.S. Tilvis, and Y.A. Kesaniemi Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population Am J Epidemiol 131 1990 20 31
24. P. Simonen, A. Kotronen, and M. Hallikainen Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity J Hepatol 54 2011 153 159
25. P. Puri, R.A. Baillie, and M.M. Wiest A lipidomic analysis of nonalcoholic fatty liver disease Hepatology 46 2007 1081 1090
26. P.M. Yao, and I. Tabas Free cholesterol loading of macrophages induces apoptosis involving the fas pathway J Biol Chem 275 2000 23807 23813
27. M.A. Austin Low-density lipoprotein subclass phenotypes, triglycerides and coronary heart disease D.J. Betteridge, D.R. Illingworth, J. Shepherd, Lipoproteins in Health and Disease 1999 Arnold London 611 617